This month marked an important milestone for UCSF faculty and clinicians working to take on the challenge of glioblastoma multiforme (GBM). They treated their first patient with a promising chimeric antigen receptor (CAR) T-cell therapy that was fully conceived, designed, optimized and manufactured here at UCSF.